Home / Health / Stanford's Universal Nasal Vaccine Breakthrough
Stanford's Universal Nasal Vaccine Breakthrough
27 Feb
Summary
- A universal nasal vaccine targets COVID-19, bacteria, and allergens.
- The vaccine stimulates the innate immune system for broader protection.
- Human trials are planned within three to five years.
Scientists at Stanford University are pioneering a revolutionary universal nasal vaccine aimed at providing broad protection against various respiratory pathogens. This innovative vaccine, currently in pre-clinical stages, has demonstrated the ability to induce robust immune responses in mice when challenged with SARS-CoV-2.
The vaccine's unique approach focuses on triggering the innate immune system, offering a more comprehensive defense than the adaptive immune system alone. Unlike conventional vaccines, it does not contain any components of specific viruses or pathogens, making it pathogen-agnostic.
Infectious disease specialists view this development as a potentially vital tool for future pandemics. However, they emphasize that significant work remains, including crucial human trials to establish safety and efficacy, and refining delivery methods for humans.
Professor Bali Pulendran, leading the research, stated that human studies are the next step, with the goal of confirming the vaccine's safety and effectiveness. These human trials are projected to take three to five years to complete.
